NeuroOne to Host Investor Webinar Following Recent FDA Clearance

NeuroOne Medical Technologies Corporation announced it will conduct a virtual roadshow webinar on October 7, 2025, at 8:30 a.m. Eastern Standard Time. The webinar will focus on the company's business operations, recent FDA clearance, and corporate updates. This presentation comes at a significant time for the medical technology company as it advances its neurological treatment solutions.

The virtual event will include a formal presentation followed by a question-and-answer session, providing investors and stakeholders with comprehensive insights into the company's progress. Participants can access the webinar through the provided webcast link at https://www.webcaster4.com/Webcast/Page/2916/53045 or by dialing 888-506-0062 for U.S. callers or 973-528-0011 for international participants, using access code 619723. The company recommends joining at least five minutes before the scheduled start time to ensure timely participation.

NeuroOne's recent FDA clearance represents a critical milestone for the company and the broader neurological treatment landscape. The company specializes in developing minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for patients suffering from various neurological disorders. These technologies target conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries.

The implications of NeuroOne's advancements extend beyond immediate patient care to potentially reducing procedural costs and improving treatment outcomes. As neurological disorders affect millions worldwide, the company's innovations could significantly impact healthcare delivery and patient quality of life. The upcoming webinar provides an opportunity for the investment community to understand how these developments position NeuroOne within the competitive medical technology sector.

A playback of the webinar will be available through October 21, 2025, for those unable to attend the live session. Interested parties can access the recording by calling 877-481-4010 within the United States or 919-882-2331 internationally, using replay passcode 53045. This extended availability ensures broader access to the company's updates and future direction.

NeuroOne's focus on neurological disorder treatments addresses a growing healthcare need as populations age and neurological conditions become more prevalent. The company's potential expansion into additional applications, including depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence integration, suggests a comprehensive approach to neurological and related conditions. For more information about the company's technologies and developments, visit https://nmtc1.com.

The investor webinar represents a strategic communication effort by NeuroOne to maintain transparency with stakeholders while showcasing recent achievements and future prospects. As the company continues to develop innovative solutions for neurological disorders, such events provide crucial platforms for sharing progress and building investor confidence in the company's mission to enhance surgical care options and patient outcomes.